

1. Record Nr.	UNINA9910457192503321
Titolo	Advances in medicine and biology [[electronic resource]] . Volume 6 // Leon V. Berhardt, editor
Pubbl/distr/stampa	New York, : Nova Biomedical Books, c2010
ISBN	1-61728-045-3
Descrizione fisica	1 online resource (296 p.)
Collana	Advances in Medicine and Biology ; ; v.6
Altri autori (Persone)	BerhardtLeon V
Disciplina	616
Soggetti	Medicine Biology Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	<p>""ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6""; ""CONTENTS""; ""PREFACE""; ""ZINC-BASED BIOMATERIALS""; ""BIOLOGICAL ASPECTS OF ZINC""; ""ZINC BIOMATERIALS""; ""ZINC OXYCHLORIDE CEMENTS""; ""ZINC OXIDE EUGENOL CEMENTS""; ""ZINC PHOSPHATE CEMENTS""; ""ZINC POLYCARBOXYLATE CEMENTS""; ""GLASS POLY(ALKENOATE) CEMENTS""; ""GLASSES USED IN GPCS""; ""ACID COMPONENTS USED IN GPCS""; ""THE ROLE OF ADDITIVES TO GPCS""; ""MECHANICAL PROPERTIES OF GPCS""; ""BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS""; ""ALUMINIUM FREE GPCS""; ""STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES""</p> <p>""STRENGTH OF ALUMINIUM-FREE GPCS""""OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS""; ""IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""OTHER ASPECTS OF ALUMINIUM-FREE GPCS""; ""APPLICATIONS FOR ALUMINIUM-FREE GPCS""; ""FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS""; ""REFERENCES""; ""THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA""; ""ABSTRACT""; ""INTRODUCTION""; ""NEUROANATOMY OF SPEECH AND LANGUAGE""; ""NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE""; ""The Primary Neurotransmitters""</p> <p>""Glutamate, I³-Aminobutyric Acid and Glycine""""Neuromodulators and Hormones""; ""Catecholamines""; ""Acetylcholine""; ""Serotonin"";</p>

""DEFINITION OF FLUENCY""; ""NEUROPHARMACOLOGY OF VERBAL FLUENCY, SPEECH AND LANGUAGE""; ""Agents which Increase Cerebral Perfusion""; ""Dopaminergic Agents""; ""Amphetamines""; ""Serotonin""; ""Cholinergic Drugs""; ""Piracetam""; ""Zolpidem""; ""Amantadine""; ""Antiepileptic Agents""; ""Drugs which have Speech and Language Side Effects""; ""CLINICAL CASE""; ""CONCLUSION""; ""REFERENCES""; ""PSORIASIS AS A MULTISYSTEM INFLAMMATORY DISEASE""; ""ABSTRACT""

""1. CLINICAL FEATURES OF PSORIASIS"" ""2. TREATMENT OPTIONS FOR PSORIASIS""; ""3. PATHOGENESIS OF PSORIASIS""; ""4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORY DISORDERS""; ""5. CLINICAL LINK BETWEEN PSORIASIS AND ATHEROSCLEROSIS""; ""6. OPHTHALMIC AND RENAL MANIFESTATIONS OF PSORIASIS""; ""7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OF PSORIASIS AND OTHER INFLAMMATORY DISORDERS""; ""8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITS SYSTEMIC MANIFESTATION?""; ""9. DELINEATING PSORIASIS AS A MULTISYSTEM INFLAMMATORY DISEASE: ""5 YEAR VIEW""""; ""REFERENCES""

""REPACKAGING OF ANTI-GLAUCOMA MEDICINES: NEW THERAPEUTIC VISTAS"" ""ABSTRACT""; ""INTRODUCTION""; ""CHOLINERGIC AGENTS""; ""Pilocarpine""; ""NON-SELECTIVE ADRENERGIC AGONISTS""; ""CARBONIC ANHYDRASE INHIBITORS""; ""Acetazolamide""; ""Dorzolamide and Brinzolamide""; ""I±2-ADRENERGIC AGONIST""; ""BETA-BLOCKING AGENTS""; ""Timolol""; ""Betaxolol""; ""Levobunolol""; ""Carteolol""; ""PROSTAGLANDIN ANALOGS""; ""Unoprostone Isopropylate""; ""Latanoprost""; ""COMBINATION""; ""CONCLUSION""; ""REFERENCES""; ""THE UTILIZATION OF TECHNOLOGY IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER""; ""ABSTRACT""

""INTRODUCTION""
